A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma

Roche: Operational Stability and Defensive Strength

The Swiss conglomerate Roche positions itself as a defensive core investment and stands out for its high operational resilience. In fiscal year 2025, the company increased its revenue by 7% on a currency-adjusted basis to CHF 61.5 billion, while consolidated net income climbed to CHF 13.8 billion. To defend its dominance in oncology, management is strategically combining established immunotherapies with new modalities such as antibody-drug conjugates and has recently advanced ten new drugs to the final development phase. Analysts at Morningstar emphasize in their latest studies that Roche faces no immediate patent cliff, which strengthens the company's strategic moat. The continuous increase in the dividend to CHF 9.80 per share now makes the stock an extremely stable anchor for investors in its industry.

Galderma Group: The Growth Champion of Dermatology

As a global pure-play specialist in dermatology, the Galderma Group fits the profile of a true growth champion. In the past year, the group achieved record revenue of USD 5.2 billion, representing a currency-adjusted increase of 17.7%. The growth driver was the Therapeutic Dermatology segment, which grew by over 50%, primarily due to the successful launch of Nemluvio, contributing USD 452 million to revenue. In the field of actinic keratosis, a common precursor to skin cancer, the company dominates standard care through a broad omni-channel presence. For the current year, management expects further revenue growth of up to 20% and a core EBITDA margin of approximately 26%, which exceeds analysts' expectations and underscores its strong market position.

Vidac Pharma: Revolution Through Metabolic Correction

While large corporations defend established markets, Vidac Pharma is emerging as an innovator. With its first-in-class candidate VDA-1102, the company directly targets the Warburg effect by interrupting the fatal interaction between the enzyme hexokinase-2 and the mitochondria. This targeted metabolic correction halts uncontrolled cancer cell growth and restores programmed cell death, sparing healthy tissue. In February of this year, Vidac successfully launched a Phase 2b clinical trial for high-risk patients with actinic keratosis at the renowned Centroderm Institute. Clinical data to date support this potential, with a 40% complete remission rate and an excellent safety profile. Since the targeted enzyme also plays a key role in inflammatory diseases, the company recently launched an in vivo preclinical program for psoriasis.

In addition to its lead candidate, VDA-1102, Vidac Pharma is consistently expanding its pipeline. According to internal reports, the company is already developing VDA-1275, a high-affinity successor candidate for the treatment of solid tumors, which is currently in the preclinical phase and preparing for approval of initial clinical trials. In addition, VDA-1102 is also being tested in a Phase 2 study as an intravenous formulation for the systemic treatment of solid tumors and cutaneous T-cell lymphoma. Analysts view this depth of the pipeline as clear evidence that the biotechnology company is not dependent on a single active ingredient, but has created a resilient and scalable platform for metabolic correction in oncology.

Investment Summary: Scaling Meets Disruption

For investors, the entire healthcare sector offers opportunities for returns. Roche and Galderma score points with established business models, high cash flows, and solid market shares, but naturally exhibit more moderate share price growth due to their market capitalization. Vidac Pharma, on the other hand, offers an attractive risk-reward profile at a current valuation of around EUR 40 million, as positive trial results over the course of the year could lead to a revaluation or an acquisition. If the clinical trials are successful, Vidac Pharma's metabolic approach could overcome many of the challenges associated with conventional cancer therapies. In biotechnology in particular, the focus is often on combining multiple therapies. Vidac's technology is particularly well-suited for this purpose.